The first aceclidine-based eye drop to improve near vision in adults with presbyopia, which affects more than 100 million ...

The US Food and Drug Administration has approved Vizz eye drops. These drops improve near vision for adults over 40. Lenz ...

Detailed price information for Lenz Therapeutics Inc (LENZ-Q) from The Globe and Mail including charting and trades.

The U.S. Food and Drug Administration has approved Vizz 1.44% (aceclidine ophthalmic solution) for the treatment of ...

Known as Vizz, the once-daily eye drops treat age-related blurry near vision — also known as presbyopia — for up to 10 hours at a time.

Presbyopia is a common variant of farsightedness affecting over 128 million people in the US, including the majority of ...

Vizz, a new FDA-approved eye drop, offers adults with age related near vision loss (presbyopia) a daily, non-surgical ...

The FDA has approved VIZZ eye drops (LENZ Therapeutics, Inc.) for the treatment of presbyopia, the gradual loss of near ...

The FDA approved Vizz for the treatment of presbyopia in adults, according to a press release from Lenz ...

Lenz Therapeutics has earned the FDA’s go-ahead for its aceclidine eye drop to crack the large presbyopia market, where past ...

VIZZ doesn’t present the same complications because it uses aceclidine instead of pilocarpine hydrochloride. Rather than significantly stimulating the ciliary muscle, VIZZ only affects the ...

Vizz contracts the iris sphincter muscle resulting in a pinhole effect, achieving a pupil <2 mm, which extends depth of focus to significantly improve near vision without causing a myopic shift.